首页 > 最新文献

Cardiovascular & hematological disorders drug targets最新文献

英文 中文
Atherosclerosis Potential Drug Targets: Current Scenario and Future Perspectives. 动脉粥样硬化潜在药物靶点:现状和未来展望。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X262041230922043156
Omar Mohammed Ali Saleh Al Qarawani, Palwinder Kaur, Manish Vyas, Sandeep Sharma

Background: The global burden of atherosclerosis and its implication to cause coronary heart disease and ischemic cardiac problems is the most prevalent cause of morbidity and hospitalization. In the US, there has been an increase in the number of patients with cardiac problems in the last decade, and still remains the primary cause of death in Europe as well as in the US.

Objectives: Even though therapeutic interventions and early diagnosis the formation of the fatty lesion and its subsequent steps are possible, the therapeutic management of the disease remains questionable when clinical data is observed. There is still scope for proper target identification and biomarker recognition, which can serve as a baseline to develop efficient pharmacological agent and delivery systems so that the disease incidence and prevalence can be controlled. The present article highlights the current pathophysiological state of the disease and emerging strategies that are applied to manage the disease.

Findings: This article gives an insight into the limitations of various conventionally used therapeutic agents for disease treatment. The emerging strategies that could prove efficacious in disease treatment. This article also gives an insight into current discoveries in the field of cellular and molecular biology, such as the genetic role in causing dyslipidemia and the role of immune cells and the role of non-coding small RNA, which can set the future direction to develop therapeutics interventions for atherosclerosis.

背景:动脉粥样硬化的全球负担及其对冠心病和缺血性心脏问题的影响是发病率和住院率最高的原因。在美国,在过去十年中,心脏问题患者的数量有所增加,并且仍然是欧洲和美国的主要死亡原因。目的:尽管治疗干预和早期诊断脂肪病变的形成及其后续步骤是可能的,当观察到临床数据时,该疾病的治疗管理仍然值得怀疑。适当的靶点识别和生物标志物识别仍有空间,这可以作为开发有效药物和递送系统的基线,从而控制疾病的发生率和流行率。本文重点介绍了该疾病目前的病理生理状态以及用于治疗该疾病的新策略。研究结果:本文深入了解了各种常规治疗药物在疾病治疗中的局限性。新出现的策略可能被证明对疾病治疗有效。这篇文章还深入了解了细胞和分子生物学领域的最新发现,如引起血脂异常的遗传作用、免疫细胞的作用和非编码小RNA的作用,这可以为开发动脉粥样硬化的治疗干预措施奠定未来的方向。
{"title":"Atherosclerosis Potential Drug Targets: Current Scenario and Future Perspectives.","authors":"Omar Mohammed Ali Saleh Al Qarawani, Palwinder Kaur, Manish Vyas, Sandeep Sharma","doi":"10.2174/011871529X262041230922043156","DOIUrl":"10.2174/011871529X262041230922043156","url":null,"abstract":"<p><strong>Background: </strong>The global burden of atherosclerosis and its implication to cause coronary heart disease and ischemic cardiac problems is the most prevalent cause of morbidity and hospitalization. In the US, there has been an increase in the number of patients with cardiac problems in the last decade, and still remains the primary cause of death in Europe as well as in the US.</p><p><strong>Objectives: </strong>Even though therapeutic interventions and early diagnosis the formation of the fatty lesion and its subsequent steps are possible, the therapeutic management of the disease remains questionable when clinical data is observed. There is still scope for proper target identification and biomarker recognition, which can serve as a baseline to develop efficient pharmacological agent and delivery systems so that the disease incidence and prevalence can be controlled. The present article highlights the current pathophysiological state of the disease and emerging strategies that are applied to manage the disease.</p><p><strong>Findings: </strong>This article gives an insight into the limitations of various conventionally used therapeutic agents for disease treatment. The emerging strategies that could prove efficacious in disease treatment. This article also gives an insight into current discoveries in the field of cellular and molecular biology, such as the genetic role in causing dyslipidemia and the role of immune cells and the role of non-coding small RNA, which can set the future direction to develop therapeutics interventions for atherosclerosis.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"77-91"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54232768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the Heart's Left and Right Ventricles (EF and TAPSE) in CABG Surgery Patients before and after Cardiac Rehabilitation. 心脏康复前后CABG手术患者心脏左心室和右心室(EF和TAPSE)的评估。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X250233231017043628
Mahdi Zahedi, Fahime Safi

Background: Post-coronary artery bypass grafting (post-CABG) is a beneficial procedure for cardiac patients. However, without an appropriate cardiac rehabilitation (CR) program, patient care may be inadequate, leading to recurrent hospitalizations and heart failure. This study aims to assess the effects of a CR program on left ventricular ejection fraction (LVEF) and tricuspid annular plane systolic excursion (TAPSE) measures in post-CABG patients at Amir-almomenin, kordkuy Hospital, Golestan, Iran.

Methods: This descriptive-analytic study included 100 patients who underwent post-CABG surgery in the second half of 2020, and whose complete information was available in their medical files. An echocardiologist assessed the LVEF and TAPSE of the patients. After one month of CR procedures, these measures were reevaluated and recorded. The CR program consisted of 5 to 10 sessions of physiotherapy per patient, with 2 or 3 sessions conducted per week. It involved a four-phase therapy that included light sports activities such as running and jogging on a treadmill at a CR clinic. Data analysis was performed using SPSS software version 18.

Results: The data analysis of this study suggests that implementing a CR program for post- CABG patients can have beneficial effects. CR significantly increased the patients' LVEF, but the increase in TAPSE was not statistically significant. Furthermore, both male and female patients showed improved LVEF after the CR program. There was a non-significant inverse relationship between hospitalization duration and LVEF. Statistically, older patients had a significantly longer duration of hospitalization compared to younger patients.

Conclusion: Completion of a cardiac rehabilitation program leads to significant improvement in left ventricular function, while the improvement in right ventricular function is relatively modest. Moreover, a significant proportion of patients were able to resume their normal daily activities after completing the rehabilitation phase.

背景:冠状动脉旁路移植术(CABG)是一种有益于心脏病患者的手术。然而,如果没有适当的心脏康复(CR)计划,患者护理可能不足,导致反复住院和心力衰竭。本研究旨在评估CR程序对伊朗戈勒斯坦Kordkuy Amir Al Momenin医院冠状动脉旁路移植术后患者左心室射血分数(LVEF)和三尖瓣环平面收缩偏移(TAPSE)测量的影响,他们的医疗档案中有他们的完整信息。回声心脏病专家评估了患者的LVEF和TAPSE。CR手术一个月后,对这些措施进行重新评估并记录。CR项目包括每位患者5至10次物理治疗,每周进行2或3次。它包括四个阶段的治疗,包括轻度运动活动,如在CR诊所的跑步机上跑步和慢跑。使用SPSS软件18版进行数据分析。结果:本研究的数据分析表明,对冠状动脉搭桥术后患者实施CR程序可以产生有益的效果。CR显著增加了患者的LVEF,但TAPSE的增加没有统计学意义。此外,男性和女性患者在CR方案后均表现出LVEF改善。住院时间与LVEF呈非显著负相关。从统计数据来看,与年轻患者相比,老年患者的住院时间明显更长。结论:完成心脏康复计划可显著改善左心室功能,而右心室功能的改善相对较小。此外,相当一部分患者在完成康复阶段后能够恢复正常的日常活动。
{"title":"Assessment of the Heart's Left and Right Ventricles (EF and TAPSE) in CABG Surgery Patients before and after Cardiac Rehabilitation.","authors":"Mahdi Zahedi, Fahime Safi","doi":"10.2174/011871529X250233231017043628","DOIUrl":"10.2174/011871529X250233231017043628","url":null,"abstract":"<p><strong>Background: </strong>Post-coronary artery bypass grafting (post-CABG) is a beneficial procedure for cardiac patients. However, without an appropriate cardiac rehabilitation (CR) program, patient care may be inadequate, leading to recurrent hospitalizations and heart failure. This study aims to assess the effects of a CR program on left ventricular ejection fraction (LVEF) and tricuspid annular plane systolic excursion (TAPSE) measures in post-CABG patients at Amir-almomenin, kordkuy Hospital, Golestan, Iran.</p><p><strong>Methods: </strong>This descriptive-analytic study included 100 patients who underwent post-CABG surgery in the second half of 2020, and whose complete information was available in their medical files. An echocardiologist assessed the LVEF and TAPSE of the patients. After one month of CR procedures, these measures were reevaluated and recorded. The CR program consisted of 5 to 10 sessions of physiotherapy per patient, with 2 or 3 sessions conducted per week. It involved a four-phase therapy that included light sports activities such as running and jogging on a treadmill at a CR clinic. Data analysis was performed using SPSS software version 18.</p><p><strong>Results: </strong>The data analysis of this study suggests that implementing a CR program for post- CABG patients can have beneficial effects. CR significantly increased the patients' LVEF, but the increase in TAPSE was not statistically significant. Furthermore, both male and female patients showed improved LVEF after the CR program. There was a non-significant inverse relationship between hospitalization duration and LVEF. Statistically, older patients had a significantly longer duration of hospitalization compared to younger patients.</p><p><strong>Conclusion: </strong>Completion of a cardiac rehabilitation program leads to significant improvement in left ventricular function, while the improvement in right ventricular function is relatively modest. Moreover, a significant proportion of patients were able to resume their normal daily activities after completing the rehabilitation phase.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"104-110"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-angioplasty Psychosis Following Inferior ST-segment Elevation Myocardial Infarction: A Case Report Highlighting an Uncommon Occurrence. 下ST段抬高型心肌梗死后血管成形术后精神病:一例罕见病例报告。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X262299231017183837
Amir Shakarami

Introduction: Myocardial infarction (MI) is a common disease. Nowadays, progress in the rapid management of acute coronary syndrome (ACS) has resulted in saving time and reduction of MI complications.

Case representation: A 68-year-old male musician with a history of coronary artery disease (CAD), while playing fiddle, complained of severe compressive retrosternal chest pain. In the present study, we report a case of inferior ST-segment elevation MI with a post-angioplasty delusion of persecution.

Conclusion: Our case report has presented a distinctive occurrence of post-angioplasty psychosis following inferior ST-segment elevation myocardial infarction. The patient displayed symptoms consistent with brief psychosis, including persecutory delusions, jealousy delusions, and second-person auditory hallucinations.

引言:心肌梗死是一种常见的疾病。目前,急性冠状动脉综合征(ACS)的快速治疗取得了进展,节省了时间,减少了MI并发症。病例描述:一名68岁的男性音乐家,有冠状动脉疾病(CAD)病史,在演奏小提琴时,抱怨严重的胸骨后压迫性胸痛。在本研究中,我们报告了一例下ST段抬高型心肌梗死,并伴有血管成形术后迫害妄想症。结论:我们的病例报告显示,下ST段抬高型心肌梗死后血管成形术后精神病的发生率很高。患者表现出与短暂精神病一致的症状,包括迫害妄想、嫉妒妄想和第二人称幻听。
{"title":"Post-angioplasty Psychosis Following Inferior ST-segment Elevation Myocardial Infarction: A Case Report Highlighting an Uncommon Occurrence.","authors":"Amir Shakarami","doi":"10.2174/011871529X262299231017183837","DOIUrl":"10.2174/011871529X262299231017183837","url":null,"abstract":"<p><strong>Introduction: </strong>Myocardial infarction (MI) is a common disease. Nowadays, progress in the rapid management of acute coronary syndrome (ACS) has resulted in saving time and reduction of MI complications.</p><p><strong>Case representation: </strong>A 68-year-old male musician with a history of coronary artery disease (CAD), while playing fiddle, complained of severe compressive retrosternal chest pain. In the present study, we report a case of inferior ST-segment elevation MI with a post-angioplasty delusion of persecution.</p><p><strong>Conclusion: </strong>Our case report has presented a distinctive occurrence of post-angioplasty psychosis following inferior ST-segment elevation myocardial infarction. The patient displayed symptoms consistent with brief psychosis, including persecutory delusions, jealousy delusions, and second-person auditory hallucinations.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"212-214"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Novel Hematological Indices with Severity of Coronary Artery Disease using SYNTAX Score in Patients with Acute Coronary Syndrome. 急性冠脉综合征患者新血液学指标与冠状动脉疾病严重程度的关联
Pub Date : 2023-01-01 DOI: 10.2174/011871529X269740231102045028
Vivek Mohanty, Shubham Sharma, Sourabh Goswami, Atul Kaushik, Rahul Choudhary, Dharamveer Yadav, Surender Deora, Kuldeep Singh

Introduction: Recent evidence suggests that systemic inflammation not only plays an important role in the pathogenesis of Acute Coronary Syndrome but also correlates with disease severity. Monocyte-to-high-density lipoprotein cholesterol ratio (MHR), Neutrophil-Lymphocyte Ratio (NLR), and Monocyte-Lymphocyte Ratio (MLR) are novel systemic inflammation markers used for predicting the burden of coronary artery disease (CAD) based on SYNTAX Score. This single-center, cross-sectional, observational study compared the association of these novel hematological indices with CAD severity using the SYNTAX Score in ACS patients and aimed to determine the best predictor of the severity of CAD.

Methods: A total of 403 consecutive patients with ACS who underwent coronary angiography were enrolled. On the basis of the SYNTAX Score, patients were divided into three groups: Low: <22, Moderate 22 - 32 and High ≥ 32. MHR, MLR, and NLR were calculated and correlated with SYNTAX Score.

Results: All three indices: MHR (r=0.511; p <0.001), MLR (r=0.373; p <0.001), and NLR (r=0.292; p =0.001) showed significant correlation with SYNTAX Score. The MHR ROC was significantly higher than that of MLR (difference between area: 0.158; 95% CI: 0.079-0.259) and NLR (difference between area: 0.279; 95% CI: 0.172-0.419) for the SYNTAX Score. Analysis showed a strong correlation between these indices with SYNTAX Score >22 compared to low scores <22 and that these also related to the LAD as an infarct artery. Multiple regression analysis showed that diabetes mellitus, eGFR, Infarct-related artery left anterior descending (IRALAD), MHR, MLR, and NLR were predictors of the severity of CAD in ACS patients based on SYNTAX Score.

Conclusion: In ACS patients MHR, MLR, and NLR showed significant correlation with SYNTAX score >22 which may be indicative of severity of disease. MHR is a better predictor of the severity of CAD than MLR and NLR in ACS patients.

最近的证据表明,全身性炎症不仅在急性冠状动脉综合征的发病机制中起重要作用,而且与疾病的严重程度有关。单核细胞-高密度脂蛋白胆固醇比值(MHR)、中性粒细胞-淋巴细胞比值(NLR)和单核细胞-淋巴细胞比值(MLR)是基于SYNTAX评分预测冠状动脉疾病(CAD)负担的新型全身炎症标志物。这项单中心、横断面、观察性研究使用ACS患者SYNTAX评分比较了这些新的血液学指标与CAD严重程度的关系,旨在确定CAD严重程度的最佳预测指标。方法:共纳入403例连续行冠脉造影的ACS患者。根据SYNTAX评分将患者分为三组:Low: Results:三个指标均为:MHR (r=0.511);结论:ACS患者MHR、MLR、NLR与Syntax评分bbbb22有显著相关性,可作为病情严重程度的指标。在ACS患者中,MHR比MLR和NLR更能预测CAD的严重程度。
{"title":"Association of Novel Hematological Indices with Severity of Coronary Artery Disease using SYNTAX Score in Patients with Acute Coronary Syndrome.","authors":"Vivek Mohanty, Shubham Sharma, Sourabh Goswami, Atul Kaushik, Rahul Choudhary, Dharamveer Yadav, Surender Deora, Kuldeep Singh","doi":"10.2174/011871529X269740231102045028","DOIUrl":"10.2174/011871529X269740231102045028","url":null,"abstract":"<p><strong>Introduction: </strong>Recent evidence suggests that systemic inflammation not only plays an important role in the pathogenesis of Acute Coronary Syndrome but also correlates with disease severity. Monocyte-to-high-density lipoprotein cholesterol ratio (MHR), Neutrophil-Lymphocyte Ratio (NLR), and Monocyte-Lymphocyte Ratio (MLR) are novel systemic inflammation markers used for predicting the burden of coronary artery disease (CAD) based on SYNTAX Score. This single-center, cross-sectional, observational study compared the association of these novel hematological indices with CAD severity using the SYNTAX Score in ACS patients and aimed to determine the best predictor of the severity of CAD.</p><p><strong>Methods: </strong>A total of 403 consecutive patients with ACS who underwent coronary angiography were enrolled. On the basis of the SYNTAX Score, patients were divided into three groups: Low: <22, Moderate 22 - 32 and High ≥ 32. MHR, MLR, and NLR were calculated and correlated with SYNTAX Score.</p><p><strong>Results: </strong>All three indices: MHR (r=0.511; p <0.001), MLR (r=0.373; p <0.001), and NLR (r=0.292; p =0.001) showed significant correlation with SYNTAX Score. The MHR ROC was significantly higher than that of MLR (difference between area: 0.158; 95% CI: 0.079-0.259) and NLR (difference between area: 0.279; 95% CI: 0.172-0.419) for the SYNTAX Score. Analysis showed a strong correlation between these indices with SYNTAX Score >22 compared to low scores <22 and that these also related to the LAD as an infarct artery. Multiple regression analysis showed that diabetes mellitus, eGFR, Infarct-related artery left anterior descending (IRALAD), MHR, MLR, and NLR were predictors of the severity of CAD in ACS patients based on SYNTAX Score.</p><p><strong>Conclusion: </strong>In ACS patients MHR, MLR, and NLR showed significant correlation with SYNTAX score >22 which may be indicative of severity of disease. MHR is a better predictor of the severity of CAD than MLR and NLR in ACS patients.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"202-211"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced Efficacy of Carvedilol by Utilization of Solid Dispersion and Other Novel Strategies: A Review. 利用固体分散体和其他新策略增强卡维地洛的疗效综述。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X247622231101075854
Lakshita Rao, Bigul Yogeshver Bhardwaj, Mahek Chugh, Ashish Sharma, Rashmi Shah, Neha Minocha, Parijat Pandey

Carvedilol is classified as a second class drug of Biopharmaceutical classification system (BCS), and it is an excellent beta blocker and vasodilating agent. It is used in a diverse range of disease states. Despite having tremendous advantages, the drug cannot be used effectively and productively due to aquaphobicity and poor bioavailability. To overcome this limitation, numerous novel approaches and tactics have been introduced over the past few years, such as Selfmicro emulsifying drug delivery systems (SMEDDS), nanoparticles, solid dispersions and liposomal drug delivery. The present review aims to accentuate the role of solid dispersion in improving the dissolution profile and aqua solubility of carvedilol and also to emphasize other novel formulations of carvedilol proposed to prevail the limitations of carvedilol. Solid dispersion and other novel approaches were found to play a significant role in overcoming the drawbacks of carvedilol, among which solid dispersion is the most feasible and effective approach being used worldwide. Reduced particle size, more wettability, and large surface area are obtained by the implementation of solid dispersion technique, hence improving carvedilol solubility and bioavailability.

卡维地洛被生物制药分类系统(BCS)列为第二类药物,是一种优良的受体阻滞剂和血管舒张剂。它用于多种疾病状态。尽管具有巨大的优势,但由于疏水性和生物利用度差,药物不能有效地利用和生产。为了克服这一限制,在过去的几年中,已经引入了许多新的方法和策略,例如自微乳化药物递送系统(SMEDDS)、纳米颗粒、固体分散体和脂质体药物递送。本文着重介绍了固体分散体在改善卡维地洛的溶出度和水溶性方面的作用,并介绍了卡维地洛的其他新配方,以克服卡维地洛的局限性。固体分散和其他新方法在克服卡维地洛的缺点方面发挥了重要作用,其中固体分散是目前世界范围内最可行、最有效的方法。通过固体分散技术的实施,获得了更小的颗粒尺寸、更大的润湿性和更大的表面积,从而提高了卡维地洛的溶解度和生物利用度。
{"title":"Enhanced Efficacy of Carvedilol by Utilization of Solid Dispersion and Other Novel Strategies: A Review.","authors":"Lakshita Rao, Bigul Yogeshver Bhardwaj, Mahek Chugh, Ashish Sharma, Rashmi Shah, Neha Minocha, Parijat Pandey","doi":"10.2174/011871529X247622231101075854","DOIUrl":"10.2174/011871529X247622231101075854","url":null,"abstract":"<p><p>Carvedilol is classified as a second class drug of Biopharmaceutical classification system (BCS), and it is an excellent beta blocker and vasodilating agent. It is used in a diverse range of disease states. Despite having tremendous advantages, the drug cannot be used effectively and productively due to aquaphobicity and poor bioavailability. To overcome this limitation, numerous novel approaches and tactics have been introduced over the past few years, such as Selfmicro emulsifying drug delivery systems (SMEDDS), nanoparticles, solid dispersions and liposomal drug delivery. The present review aims to accentuate the role of solid dispersion in improving the dissolution profile and aqua solubility of carvedilol and also to emphasize other novel formulations of carvedilol proposed to prevail the limitations of carvedilol. Solid dispersion and other novel approaches were found to play a significant role in overcoming the drawbacks of carvedilol, among which solid dispersion is the most feasible and effective approach being used worldwide. Reduced particle size, more wettability, and large surface area are obtained by the implementation of solid dispersion technique, hence improving carvedilol solubility and bioavailability.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"141-156"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Perspective and Mechanistic Insights on Bioactive Plant Secondary Metabolites for the Prevention and Treatment of Cardiovascular Diseases. 用于预防和治疗心血管疾病的生物活性植物次级代谢产物的当前前景和机制见解。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X262371231009132426
Jyotika Grewal, Vijay Kumar, Yashika Gandhi, Hemant Rawat, Ravindra Singh, Arjun Singh, Ch V Narasimhaji, Rabinarayan Acharya, Sujeet K Mishra

Cardiovascular diseases (CVDs) are one of the most prevalent medical conditions of modern era and are one of the primary causes of adult mortality in both developing and developed countries. Conventional medications such as use of aspirin, beta-blockers, statins and angiotensin- converting enzyme inhibitors involve use of drugs with many antagonistic effects. Hence, alternative therapies which are safe, effective, and relatively cheap are increasingly being investigated for the treatment and prevention of CVDs. The secondary metabolites of medicinal plants contain several bioactive compounds which have emerged as alternatives to toxic modern medicines. The detrimental effects of CVDs can be mitigated via the use of various bioactive phytochemicals such as catechin, isoflavones, quercetin etc. present in medicinal plants. Current review intends to accumulate previously published data over the years using online databases concerning herbal plant based secondary metabolites that can help in inhibition and treatment of CVDs. An in-depth review of various phytochemical constituents with therapeutic actions such as antioxidant, anti-inflammatory, vasorelaxant, anti-hypertensive and cardioprotective properties has been delineated. An attempt has been made to provide a probable mechanistic overview for the pertinent phytoconstituent which will help in achieving a better prognosis and effective treatment for CVDs.

心血管疾病是现代最常见的疾病之一,也是发展中国家和发达国家成年人死亡的主要原因之一。常规药物如阿司匹林、β受体阻滞剂、他汀类药物和血管紧张素转换酶抑制剂的使用涉及到具有许多拮抗作用的药物的使用。因此,越来越多地研究安全、有效且相对便宜的替代疗法来治疗和预防心血管疾病。药用植物的次生代谢产物含有几种生物活性化合物,这些化合物已成为现代有毒药物的替代品。CVDs的有害影响可以通过使用药用植物中存在的各种生物活性植物化学物质,如儿茶素、异黄酮、槲皮素等来减轻。目前的综述旨在利用在线数据库积累多年来先前发表的关于草药植物次生代谢产物的数据,这些数据可以帮助抑制和治疗心血管疾病。对具有抗氧化、抗炎、血管舒张、抗高血压和心脏保护等治疗作用的各种植物化学成分进行了深入的综述。已经尝试为相关的植物成分提供一个可能的机制概述,这将有助于获得更好的预后和对心血管疾病的有效治疗。
{"title":"Current Perspective and Mechanistic Insights on Bioactive Plant Secondary Metabolites for the Prevention and Treatment of Cardiovascular Diseases.","authors":"Jyotika Grewal, Vijay Kumar, Yashika Gandhi, Hemant Rawat, Ravindra Singh, Arjun Singh, Ch V Narasimhaji, Rabinarayan Acharya, Sujeet K Mishra","doi":"10.2174/011871529X262371231009132426","DOIUrl":"10.2174/011871529X262371231009132426","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) are one of the most prevalent medical conditions of modern era and are one of the primary causes of adult mortality in both developing and developed countries. Conventional medications such as use of aspirin, beta-blockers, statins and angiotensin- converting enzyme inhibitors involve use of drugs with many antagonistic effects. Hence, alternative therapies which are safe, effective, and relatively cheap are increasingly being investigated for the treatment and prevention of CVDs. The secondary metabolites of medicinal plants contain several bioactive compounds which have emerged as alternatives to toxic modern medicines. The detrimental effects of CVDs can be mitigated via the use of various bioactive phytochemicals such as catechin, isoflavones, quercetin etc. present in medicinal plants. Current review intends to accumulate previously published data over the years using online databases concerning herbal plant based secondary metabolites that can help in inhibition and treatment of CVDs. An in-depth review of various phytochemical constituents with therapeutic actions such as antioxidant, anti-inflammatory, vasorelaxant, anti-hypertensive and cardioprotective properties has been delineated. An attempt has been made to provide a probable mechanistic overview for the pertinent phytoconstituent which will help in achieving a better prognosis and effective treatment for CVDs.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"157-176"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. 保留射血分数的心力衰竭患者肺动脉高压药物治疗的最新进展。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X258234230921112507
Fernando Segovia, Hernando Garcia, Haider Alkhateeb, Debabrata Mukherjee, Nils Nickel

Pulmonary hypertension (PH) associated with left heart disease (LHD) is a complex cardiopulmonary condition where a variable degree of pulmonary congestion, arterial vasoconstriction and vascular remodeling can lead to PH and right heart strain. Right heart dysfunction has a significant prognostic impact on these patients. Therefore, preserving right ventricular (RV) function is an important treatment goal. However, the treatment of PH in patients with left heart disease has produced conflicting evidence. The transition from pure LHD to LHD with PH is a continuum and clinically challenging. The heart failure with preserved ejection fraction (HFpEF) patient population is heterogeneous when it comes to PH and RV function. Appropriate clinical and hemodynamic phenotyping of patients with HFpEF and concomitant PH is paramount to making the appropriate treatment decision. This manuscript will summarize the current evidence for the use of pulmonary arterial vasodilators in patients with HFpEF.

与左心疾病(LHD)相关的肺动脉高压(PH)是一种复杂的心肺疾病,不同程度的肺充血、动脉血管收缩和血管重塑会导致肺动脉高压和右心劳损。右心功能不全对这些患者的预后有重要影响。因此,保留右心室(RV)功能是一个重要的治疗目标。然而,左心病患者PH的治疗产生了相互矛盾的证据。从纯LHD到带PH的LHD的转变是一个连续的过程,在临床上具有挑战性。射血分数保留的心力衰竭(HFpEF)患者群体在PH和RV功能方面是异质性的。HFpEF和伴发PH患者的适当临床和血液动力学表型对于做出适当的治疗决定至关重要。本文将总结目前在HFpEF患者中使用肺动脉血管舒张剂的证据。
{"title":"Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction.","authors":"Fernando Segovia, Hernando Garcia, Haider Alkhateeb, Debabrata Mukherjee, Nils Nickel","doi":"10.2174/011871529X258234230921112507","DOIUrl":"10.2174/011871529X258234230921112507","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) associated with left heart disease (LHD) is a complex cardiopulmonary condition where a variable degree of pulmonary congestion, arterial vasoconstriction and vascular remodeling can lead to PH and right heart strain. Right heart dysfunction has a significant prognostic impact on these patients. Therefore, preserving right ventricular (RV) function is an important treatment goal. However, the treatment of PH in patients with left heart disease has produced conflicting evidence. The transition from pure LHD to LHD with PH is a continuum and clinically challenging. The heart failure with preserved ejection fraction (HFpEF) patient population is heterogeneous when it comes to PH and RV function. Appropriate clinical and hemodynamic phenotyping of patients with HFpEF and concomitant PH is paramount to making the appropriate treatment decision. This manuscript will summarize the current evidence for the use of pulmonary arterial vasodilators in patients with HFpEF.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"215-225"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective Effect of Hydroalcoholic Extract of Punica granatum Leaves on High Fructose Induced Insulin Resistance in Experimental Animals. 石榴叶水醇提取物对高果糖诱导的胰岛素抵抗的保护作用。
Pub Date : 2023-01-01 DOI: 10.2174/011871529X273808231129035950
Deepti Bandawane, Ashwini Kotkar, Pooja Ingole

Background: Insulin resistance (IR) is a condition characterized by reduced sensitivity of body tissues to insulin, leading to impaired regulation of downstream metabolic pathways and elevated blood glucose levels. Diets rich in fructose have been proven to cause insulin resistance in test rats, resulting in decreased insulin sensitivity, particularly in the liver, and compromised disposal of glucose from the body. In the search for effective treatments, Plant-derived formulations have gained popularity because to their ability for treating a variety of ailments. One such plant is Punica granatum Linn. from the Punicaceae family, which has long been used in the treatment of diabetes and its consequences. This study investigates the insulin-resistant activity of an extract from Punica granatum leaves. The study goal is to assess the possible protective role of Punica granatum against insulin resistance through various analyses, including serum glucose and insulin levels, lipid profile assessment, measurement of liver enzymes (ALP, SGOT, SGPT), and histopathological examination of liver sections.

Methods: The study involves several key methods to evaluate the insulin-resistant activity of Punica granatum extract in high fructose diet induced insulin resistance animal model. The extract was administered orally to the experimental animals. These methods include the measurement of serum glucose and serum insulin levels, analysis of the lipid profile, quantification of liver enzymes such as ALP, SGOT, and SGPT, and a detailed histopathological examination of liver tissue sections. These analyses collectively provide insights into the impact of Punica granatum extract on insulin resistance and related metabolic parameters.

Results: Findings of this study provide insight on the possible benefits of Punica granatum extract on insulin resistance. Through the assessment of serum glucose and insulin levels, lipid profile analysis, and measurement of liver enzymes, the study elucidates the impact of the extract on key metabolic indicators. Additionally, the histopathological examination of liver sections provides visual insights into the structural changes that may occur as a result of the treatment.

Conclusion: In conclusion, this study highlights the ability of Punica granatum extract as a candidate for addressing insulin resistance. The findings suggest that the extract may have a protective role against insulin resistance, as evidenced by improvements in serum glucose and insulin levels, lipid profile, liver enzyme levels, and histopathological characteristics. Further research and investigations are warranted to fully understand the mechanisms underlying these observed effects and to validate the potential of Punica granatum extract as a therapeutic option for managing insulin resistance and its associated compl

背景:胰岛素抵抗(Insulin resistance, IR)是机体组织对胰岛素敏感性降低,导致下游代谢途径调节受损和血糖水平升高的一种疾病。富含果糖的饮食已被证明会引起实验鼠的胰岛素抵抗,导致胰岛素敏感性降低,尤其是肝脏的胰岛素敏感性降低,并影响体内葡萄糖的处理。在寻找有效治疗方法的过程中,植物衍生制剂因其治疗多种疾病的能力而广受欢迎。其中一种植物是石榴属植物。来自石榴科,长期以来一直用于治疗糖尿病及其后果。本研究探讨了石榴叶提取物的胰岛素抵抗活性。研究目的是通过各种分析,包括血清葡萄糖和胰岛素水平,血脂评估,肝酶(ALP, SGOT, SGPT)测量和肝脏切片的组织病理学检查,评估石榴对胰岛素抵抗可能的保护作用。方法:采用几种关键方法评价石榴提取物在高果糖饮食诱导胰岛素抵抗动物模型中的胰岛素抵抗活性。该提取物被口服给实验动物。这些方法包括测定血清葡萄糖和血清胰岛素水平,分析血脂,定量测定肝酶,如ALP、SGOT和SGPT,以及详细的肝组织切片组织病理学检查。这些分析共同为石榴提取物对胰岛素抵抗和相关代谢参数的影响提供了见解。结果:本研究结果揭示了石榴提取物对胰岛素抵抗的可能益处。通过血清葡萄糖和胰岛素水平评估、血脂分析和肝酶测定,研究阐明了提取物对关键代谢指标的影响。此外,肝脏切片的组织病理学检查可以直观地了解治疗后可能发生的结构变化。结论:总之,本研究强调了石榴提取物作为解决胰岛素抵抗的候选物的能力。研究结果表明,提取物可能对胰岛素抵抗有保护作用,如改善血清葡萄糖和胰岛素水平、脂质谱、肝酶水平和组织病理学特征。进一步的研究和调查是必要的,以充分了解这些观察到的影响的机制,并验证石榴提取物作为治疗胰岛素抵抗及其相关并发症的治疗选择的潜力。
{"title":"Protective Effect of Hydroalcoholic Extract of <i>Punica granatum</i> Leaves on High Fructose Induced Insulin Resistance in Experimental Animals.","authors":"Deepti Bandawane, Ashwini Kotkar, Pooja Ingole","doi":"10.2174/011871529X273808231129035950","DOIUrl":"10.2174/011871529X273808231129035950","url":null,"abstract":"<p><strong>Background: </strong>Insulin resistance (IR) is a condition characterized by reduced sensitivity of body tissues to insulin, leading to impaired regulation of downstream metabolic pathways and elevated blood glucose levels. Diets rich in fructose have been proven to cause insulin resistance in test rats, resulting in decreased insulin sensitivity, particularly in the liver, and compromised disposal of glucose from the body. In the search for effective treatments, Plant-derived formulations have gained popularity because to their ability for treating a variety of ailments. One such plant is <i>Punica granatum</i> Linn. from the Punicaceae family, which has long been used in the treatment of diabetes and its consequences. This study investigates the insulin-resistant activity of an extract from <i>Punica granatum</i> leaves. The study goal is to assess the possible protective role of <i>Punica granatum</i> against insulin resistance through various analyses, including serum glucose and insulin levels, lipid profile assessment, measurement of liver enzymes (ALP, SGOT, SGPT), and histopathological examination of liver sections.</p><p><strong>Methods: </strong>The study involves several key methods to evaluate the insulin-resistant activity of <i>Punica granatum</i> extract in high fructose diet induced insulin resistance animal model. The extract was administered orally to the experimental animals. These methods include the measurement of serum glucose and serum insulin levels, analysis of the lipid profile, quantification of liver enzymes such as ALP, SGOT, and SGPT, and a detailed histopathological examination of liver tissue sections. These analyses collectively provide insights into the impact of <i>Punica granatum</i> extract on insulin resistance and related metabolic parameters.</p><p><strong>Results: </strong>Findings of this study provide insight on the possible benefits of <i>Punica granatum</i> extract on insulin resistance. Through the assessment of serum glucose and insulin levels, lipid profile analysis, and measurement of liver enzymes, the study elucidates the impact of the extract on key metabolic indicators. Additionally, the histopathological examination of liver sections provides visual insights into the structural changes that may occur as a result of the treatment.</p><p><strong>Conclusion: </strong>In conclusion, this study highlights the ability of <i>Punica granatum</i> extract as a candidate for addressing insulin resistance. The findings suggest that the extract may have a protective role against insulin resistance, as evidenced by improvements in serum glucose and insulin levels, lipid profile, liver enzyme levels, and histopathological characteristics. Further research and investigations are warranted to fully understand the mechanisms underlying these observed effects and to validate the potential of <i>Punica granatum</i> extract as a therapeutic option for managing insulin resistance and its associated compl","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":"263-276"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital Bleeding Disorders and COVID-19 ─ an Emphasis on the Role of Thrombosis as One of the Main Causes of Morbidity and Mortality in COVID-19. 先天性出血性疾病与COVID-19──强调血栓形成是COVID-19发病和死亡的主要原因之一。
Pub Date : 2022-06-14 DOI: 10.2174/1871529X22666220614090005
A. Dorgalaleh, Fateme Narouei, Mansur Asadi, Hassan Morovati Khamsi, M. Gholami
A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19), with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up observations revealed this effect, at least among patients with moderate to severe congenital bleeding disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19.
湍流凝血系统是2019冠状病毒病(COVID-19)的一个突出特征,静脉血栓栓塞(VTE)是主要死亡原因。我们的假设是,遗传性低凝性患者,如先天性出血性疾病(CBD),对covid -19诱导的高凝性和相关致命后果具有保护作用。我们的初步和随访观察显示了这种效果,至少在中度至重度先天性出血性疾病,特别是凝血因子缺乏的患者中是如此。从理论上讲,遗传性低凝性患者对covid -19相关的高凝性只有潜在的保护作用。然而,CBDs患者较低的发病率和死亡率表明,高凝性和血栓形成事件是COVID-19患者死亡的主要原因。因此,适当、及时地使用抗凝药物可显著降低COVID-19的发病率和死亡率。
{"title":"Congenital Bleeding Disorders and COVID-19 ─ an Emphasis on the Role of Thrombosis as One of the Main Causes of Morbidity and Mortality in COVID-19.","authors":"A. Dorgalaleh, Fateme Narouei, Mansur Asadi, Hassan Morovati Khamsi, M. Gholami","doi":"10.2174/1871529X22666220614090005","DOIUrl":"https://doi.org/10.2174/1871529X22666220614090005","url":null,"abstract":"A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19), with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up observations revealed this effect, at least among patients with moderate to severe congenital bleeding disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90345191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pre-admission beta-blocker therapy and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. 入院前β受体阻滞剂治疗和2019冠状病毒病(COVID-19)的结局:系统评价、荟萃分析和荟萃回归
Pub Date : 2022-04-20 DOI: 10.2174/1871529X22666220420112735
T. Hariyanto, Joshua Edward Hananto, D. Intan, A. Kurniawan
BACKGROUNDHypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between pre-admission beta-blocker use and COVID-19 outcomes.METHODSPubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID-19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis.RESULTSA total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Meta-regression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005).CONCLUSIONSThe risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be put into account and reviewed individually case by case, knowing their association in higher incidence and severity of Covid-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweigh the benefits in Covid-19 infection.
背景:高血压和心力衰竭是2019冠状病毒病(COVID-19)严重程度和死亡率结果的已知危险因素。受体阻滞剂是治疗这些疾病的首选药物之一。本研究的目的是探讨入院前β受体阻滞剂使用与COVID-19结局之间的关系。方法使用spubmed和Europe PMC作为数据库,结合我们目标的关键词进行搜索策略,截止到2020年12月10日。检索所有与COVID-19和β -受体阻滞剂相关的文章。采用Review Manager 5.4和Comprehensive Meta-Analysis 3软件进行统计分析。结果共纳入43项研究,11,388,556例患者。我们的荟萃分析显示,β受体阻滞剂的使用与COVID-19的风险增加[OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%,随机效应模型]、临床进展[OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%,随机效应模型]和COVID-19的死亡率[OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%,随机效应模型]相关。meta回归结果显示,年龄(p = 0.018)和高血压(p = 0.005)影响与死亡率结局的相关性。结论乙型受体阻滞剂作为治疗高血压患者的首选药物,应考虑其风险和获益,并逐案评估,了解其与Covid-19感染的高发病率和严重程度的关系。如果在Covid-19感染中使用受体阻滞剂的风险超过益处,则可以考虑使用其他一线降压药物作为替代疗法。
{"title":"Pre-admission beta-blocker therapy and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.","authors":"T. Hariyanto, Joshua Edward Hananto, D. Intan, A. Kurniawan","doi":"10.2174/1871529X22666220420112735","DOIUrl":"https://doi.org/10.2174/1871529X22666220420112735","url":null,"abstract":"BACKGROUND\u0000Hypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between pre-admission beta-blocker use and COVID-19 outcomes.\u0000\u0000\u0000METHODS\u0000PubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID-19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis.\u0000\u0000\u0000RESULTS\u0000A total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Meta-regression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005).\u0000\u0000\u0000CONCLUSIONS\u0000The risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be put into account and reviewed individually case by case, knowing their association in higher incidence and severity of Covid-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweigh the benefits in Covid-19 infection.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91369874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Cardiovascular & hematological disorders drug targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1